Skip to content
Study details
Enrolling now

VENTURI Trial

University of Alabama at Birmingham
NCT IDNCT07282886ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

20

Study length

about 5 years

Ages

18–75

Locations

1 site in AL

What this study is about

This trial is testing a treatment for asthma. It compares two different inhaler medications to see which one works best in people with uncontrolled asthma.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI
  • 2.Take Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
inhaledtopical

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Anti-inflammatory Agent (Corticosteroid Hormone Receptor Agonists), fluticasone furoate, Respiratory System Agent (Adrenergic beta2-Agonists), Central Nervous System Agent (Cholinergic Muscarinic Antagonists), Respiratory System Agent (Cholinergic Antagonists)

Drug routes

inhaled, topical (Topical Cream), oral (Oral Tablet)

Endpoints

Primary: Evaluate the effect of extrafine beclomethasone dipropionate/formoterol fumarate /glycopyrrolate compared with non-extrafine fluticasone furoate/ umeclidinium/vilanterol on ventilation defect percentage utilizing 129Xenon MRI.

Body systems

Respiratory